Fibroblast Growth Factor 21 in Metabolic Syndrome

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2023 Aug 14

PMID 37576954

Authors

Ming Yang

Chongbin Liu

Na Jiang

Yan Liu

Shilu Luo

Chenrui Li

Hao Zhao

Yachun Han

Wei Chen

Li Li

Li Xiao

Lin Sun

Affiliations

Soon will be listed here.

Abstract

Metabolic syndrome is a complex metabolic disorder that often clinically manifests as obesity, insulin resistance/diabetes, hyperlipidemia, and hypertension. With the development of social and economic systems, the incidence of metabolic syndrome is increasing, bringing a heavy medical burden. However, there is still a lack of effective prevention and treatment strategies. Fibroblast growth factor 21 (FGF21) is a member of the human FGF superfamily and is a key protein involved in the maintenance of metabolic homeostasis, including reducing fat mass and lowering hyperglycemia, insulin resistance and dyslipidemia. Here, we review the current regulatory mechanisms of FGF21, summarize its role in obesity, diabetes, hyperlipidemia, and hypertension, and discuss the possibility of FGF21 as a potential target for the treatment of metabolic syndrome.

Citing Articles

Hepatokines and their role in cardiohepatic interactions in heart failure.

Shouman W, Najmeddine S, Sinno L, Dib Nehme R, Ghawi A, Ziade J Eur J Pharmacol. 2025; 992:177356.

PMID: 39922419 PMC: 11862882. DOI: 10.1016/j.ejphar.2025.177356.

FGF21 upregulation by hepatitis C virus via the eIF2α-ATF4 pathway: implications for interferon signaling suppression and TRIM31-mediated TSC degradation.

Liu L, Ito M, Sakai S, Liu J, Ohta K, Saito K Front Microbiol. 2024; 15:1456108.

PMID: 39211324 PMC: 11357932. DOI: 10.3389/fmicb.2024.1456108.

The crosstalk between fibroblast growth factor 21 (FGF21) system and substance use.

Wang T, Tyler R, Ilaka O, Cooper D, Farokhnia M, Leggio L iScience. 2024; 27(7):110389.

PMID: 39055947 PMC: 11269927. DOI: 10.1016/j.isci.2024.110389.

A correlation of serum fibroblast growth factor 21 level with inflammatory markers and indicators of nutritional status in patients with inflammatory bowel disease.

Lukawska A, Mulak A Front Physiol. 2024; 15:1394030.

PMID: 38983722 PMC: 11231369. DOI: 10.3389/fphys.2024.1394030.

Relationship of postprandial fibroblast growth factor 21 with lipids, inflammation and metabolic dysfunction-associated fatty liver disease during oral fat tolerance test.

Li X, Zheng K, Liu L, Zhang T, Gu W, Hou X Front Endocrinol (Lausanne). 2024; 15:1343853.

PMID: 38828414 PMC: 11140040. DOI: 10.3389/fendo.2024.1343853.

References

Kharitonenkov A, DiMarchi R . FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties. Trends Endocrinol Metab. 2015; 26(11):608-617. DOI: 10.1016/j.tem.2015.09.007. View

Yan X, Chen J, Zhang C, Zhou S, Zhang Z, Chen J . FGF21 deletion exacerbates diabetic cardiomyopathy by aggravating cardiac lipid accumulation. J Cell Mol Med. 2015; 19(7):1557-68. PMC: 4511354. DOI: 10.1111/jcmm.12530. View

Lin Z, Tian H, Lam K, Lin S, Hoo R, Konishi M . Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab. 2013; 17(5):779-89. DOI: 10.1016/j.cmet.2013.04.005. View

Ong K, OConnell R, Januszewski A, Jenkins A, Xu A, Sullivan D . Baseline Circulating FGF21 Concentrations and Increase after Fenofibrate Treatment Predict More Rapid Glycemic Progression in Type 2 Diabetes: Results from the FIELD Study. Clin Chem. 2017; 63(7):1261-1270. DOI: 10.1373/clinchem.2016.270876. View

Zhang X, Ibrahimi O, Olsen S, Umemori H, Mohammadi M, Ornitz D . Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem. 2006; 281(23):15694-700. PMC: 2080618. DOI: 10.1074/jbc.M601252200. View

Sarkar S, Chen S, Spencer B, Situ X, Afkarian M, Matsukuma K . Non-Alcoholic Steatohepatitis Severity Associates with FGF21 Level and Kidney Glucose Uptake. Metab Syndr Relat Disord. 2021; 19(9):491-497. PMC: 10027339. DOI: 10.1089/met.2021.0055. View

Kilkenny D, Rocheleau J . The FGF21 Receptor Signaling Complex: Klothoβ, FGFR1c, and Other Regulatory Interactions. Vitam Horm. 2016; 101:17-58. DOI: 10.1016/bs.vh.2016.02.008. View

Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M . Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol. 2013; 12:124. PMC: 3766150. DOI: 10.1186/1475-2840-12-124. View

Zeng Z, Zheng Q, Chen J, Tan X, Li Q, Ding L . FGF21 mitigates atherosclerosis via inhibition of NLRP3 inflammasome-mediated vascular endothelial cells pyroptosis. Exp Cell Res. 2020; 393(2):112108. DOI: 10.1016/j.yexcr.2020.112108. View

10.

Gao J, Liu J, Meng Z, Li Y, Hong Y, Wang L . Ultrasound-assisted CF-filled PLGA nanobubbles for enhanced FGF21 delivery and improved prophylactic treatment of diabetic cardiomyopathy. Acta Biomater. 2021; 130:395-408. DOI: 10.1016/j.actbio.2021.06.015. View

11.

Hwang B, Kwon M, Cho M, Lee N, Lee J, Lee J . Hepatic PTP4A1 ameliorates high-fat diet-induced hepatosteatosis and hyperglycemia by the activation of the CREBH/FGF21 axis. Theranostics. 2023; 13(3):1076-1090. PMC: 9925322. DOI: 10.7150/thno.79434. View

12.

Watanabe M, Risi R, Camajani E, Contini S, Persichetti A, Tuccinardi D . Baseline HOMA IR and Circulating FGF21 Levels Predict NAFLD Improvement in Patients Undergoing a Low Carbohydrate Dietary Intervention for Weight Loss: A Prospective Observational Pilot Study. Nutrients. 2020; 12(7). PMC: 7400878. DOI: 10.3390/nu12072141. View

13.

Itoh N, Ornitz D . Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2010; 149(2):121-30. PMC: 3106964. DOI: 10.1093/jb/mvq121. View

14.

Kuzina E, Ung P, Mohanty J, Tome F, Choi J, Pardon E . Structures of ligand-occupied β-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity. Proc Natl Acad Sci U S A. 2019; 116(16):7819-7824. PMC: 6475419. DOI: 10.1073/pnas.1822055116. View

15.

Cheng Y, Zhang J, Guo W, Li F, Sun W, Chen J . Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy. Free Radic Biol Med. 2016; 93:94-109. PMC: 7446394. DOI: 10.1016/j.freeradbiomed.2016.02.002. View

16.

Sun W, Nie T, Li K, Wu W, Long Q, Feng T . Hepatic CPT1A Facilitates Liver-Adipose Cross-Talk Induction of FGF21 in Mice. Diabetes. 2021; . DOI: 10.2337/db21-0363. View

17.

Foltz I, Hu S, King C, Wu X, Yang C, Wang W . Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex. Sci Transl Med. 2012; 4(162):162ra153. DOI: 10.1126/scitranslmed.3004690. View

18.

Zhao L, Wang H, Xie J, Chen Z, Li X, Niu J . Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice. BMC Biotechnol. 2017; 17(1):58. PMC: 5496364. DOI: 10.1186/s12896-017-0368-z. View

19.

Pan X, Shao Y, Wu F, Wang Y, Xiong R, Zheng J . FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. Cell Metab. 2018; 27(6):1323-1337.e5. DOI: 10.1016/j.cmet.2018.04.002. View

20.

Gao R, Hsu B, Wu D, Hou J, Chen M . Serum Fibroblast Growth Factor 21 Levels Are Positively Associated with Metabolic Syndrome in Patients with Type 2 Diabetes. Int J Endocrinol. 2019; 2019:5163245. PMC: 6754922. DOI: 10.1155/2019/5163245. View